Semaglutide modulates explore/exploit decision-making in major depressive disorder: A randomized clinical trial
- Design
- Randomized trial · 72 participants · Surrogate outcome
- Match to healthy normal-weight adults aged 55–75
- Partial matchPARTIAL: participants were enrolled for major depressive disorder, a condition selected for itself; the abstract reports no BMI or diabetes data.
- Could weight loss explain it?
- Specifically testedThe authors report the effects were moderated by, but independent of, weight loss during the trial, which indicates a participant-level analysis that included weight change. The abstract calls it moderation rather than mediation and gives no numbers for it.
Adjusted for: body-weight change - Study tier
- Study tier 3LOW: a secondary analysis of a small randomized trial (72 participants, 16 weeks) with an exploratory computational outcome and no confidence intervals.
- Assessment
- Version 2 · Two independent AI reviews agreed · Nov 7, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
In a secondary analysis of a randomized trial, 72 people with major depression took oral semaglutide (35) or placebo (37) for 16 weeks and did a reward-learning computer task before and after. Semaglutide shifted three measures of how people chose between familiar and uncertain options, and the authors report these shifts did not depend on weight loss. Whether these changes help patients is not established, and the study is small.
01Findings
What the study reported
- Drugs
- Semaglutide
- Route
- oral
- Comparator
- placebo
- Treatment duration
- 16 weeks
- Primary outcome
- explore/exploit decision-making on a four-armed restless bandit task (computational model parameters)
- Effect
- Semaglutide vs placebo: exploitation ATE = 0.0242 (p < 0.001); directed exploration ATE = 0.0619 (p = 0.013); perseveration ATE = 0.3017 (p = 0.013); effects moderated by, but independent of, baseline characteristics and weight loss
- 95% confidence interval
- Not extracted
- P value
- p < 0.001 (exploitation); p = 0.013 (directed exploration and perseveration)
- Follow-up
- 16 weeks
- Adverse events
- not reported in abstract
- Limitations
- A small secondary analysis of a 16-week trial using a computational task measure whose clinical meaning is uncertain; no confidence intervals are reported.
Who was studied
- Baseline condition
- major depressive disorder
- Sample size
- 72
- Inclusion exclusion
- participants with major depressive disorder (MDD)
Study quality details
- Study design
- Randomized controlled trial
- Sample size
- 72
- Randomization
- yes
- Blinding
- not stated
- Comparator
- placebo
- Follow up duration
- 16 weeks
- Outcome type
- surrogate
- Replication
- not assessed
- Consistency with other evidence
- not assessed
- Population applicability
- PARTIAL
- Statistical precision
- no CI reported; p values reported; 72 participants
- Risk of bias
- not assessed
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- Physicians' Services Incorporated Foundation
- Industry funded
- Unclear
- Manufacturer
- not stated in source
- Sponsor role
- not reported in abstract
- Author conflicts
- not reported in abstract
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
04Source
The source, as retrieved
Abstract
[BACKGROUND] Explore/exploit decision-making is a crucial component of motivated behavior. Explore/exploit behaviors are related to disparate cognitive and reward-related functions and have been implicated in multiple neuropsychiatric conditions, including major depressive disorder (MDD). Several mediators of explore/exploit decision-making have been proposed; metabolic mechanisms have been theorized to potentially affect its underlying processes. Here, we examined the effects of a GLP-1 receptor agonist (GLP-1RA), semaglutide, on explore/exploit behavior in patients with MDD, using a four-armed restless bandit task. [METHODS] In this secondary analysis of a randomized clinical trial, 72 participants with MDD were randomized either to oral semaglutide (n = 35) or placebo (n = 37), and completed the bandit task at baseline and following 16 weeks of treatment. Explore/exploit decision-making was assessed using computational modeling of choice behavior, with a trial-by-trial reinforcement-learning model. [RESULTS] Treatment with semaglutide resulted in increased exploitation (i.e. choosing the option with the highest expected reward) (Average Treatment Effect [ATE] = 0.0242, p < 0.001), directed exploration (i.e. exploring a choice with higher uncertainty) (ATE = 0.0619, p = 0.013), and perseveration (i.e. the value-independent tendency to repeat the previous action) (ATE = 0.3017, p = 0.013). These effects were moderated by, but ultimately independent of, baseline characteristics and weight loss during the trial. [CONCLUSIONS] Treatment with semaglutide modulated explore/exploit behaviors in patients with MDD. These results highlight the role of metabolic mechanisms in decision-making processes in MDD and expand knowledge of the potential neuropsychiatric effects of GLP-1RAs.
Where this record came from
| Source | Retrieved | Identifier |
|---|---|---|
| pubmed | Oct 25, 2026 | 42904347 first ingestion |
| pubmed | Nov 1, 2026 | 42904347 duplicate matched on doi |
| owner-review | Nov 6, 2026 | reviewed_by set to Carrie Schluter (2026-11-05) on the owner's own confirmation. The assessment is unchanged and still the auto-classifier's, so its extracted values stay withheld under the 2026-10-18 decision. |